RxDoctor Payments Data

Ethelynda Tolentino, MD

Pain Medicine · Sacramento, CANPI 1093798092

Payments from drug & device makers

$6,823in general payments, 2019–2025

Across 283 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Electronic Waveform Lab, Inc.$3K
  • Medtronic$1K
  • Zyla Life Sciences, Inc.$417
  • Si-bone, Inc.$360
  • Abbott$292
  • Scilex Pharmaceuticals Inc.$281
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,823 in reported general payments places this provider in the 70th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$226,263
Medicare patients
432
Services billed
2,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen235$7,395
MovantikNaloxegol Oxalate13$4,496
Celecoxib44$2,848
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen73$2,774
Gabapentin144$1,718
Buprenorphine13$1,636
Lubiprostone14$1,376
Morphine Sulfate ErMorphine Sulfate42$1,259
Pregabalin27$759
Tizanidine Hcl51$414
Baclofen40$395
Duloxetine Hcl33$366
Ibuprofen49$268
Oxycodone Hcl12$190
Cyclobenzaprine Hcl24$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$20$4,49613 claims
Hikma Pharmaceuticals USABuprenorphine$17$1,63613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 840 pain medicine providers in California.

Other pain medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →